#Amyloidosis

Dr. Suzanne Lentzsch

#ISA2020 Yesterday: Plenery Session on Diagnosis and Management of AL #amyloidosis chaired by @awechalekar and Stefan Schönland. Here is my take home message @AmyloidosisSupp @Amyloidosisfdn @Amyloidosis_ARC @AmyloidC @MayoAmyloid @amyloid

An interesting contrast of the @US_FDA label for tafamidis (in ATTR-CM) vs daratumumab (in AL). NYHA class IV were excluded in ATTRACT and NYHA class IIIb and IV excluded in

And the 3rd morning of #BSR21 is kicking off. I'm starting the day with "Cardiac complications of rheumatic Disease and anti-rheumatic therapies". The first talk is by @TYoungstein on "Infiltrative

Virginia Shalkey Hahn, MD

VirginiaSHahnMD

1/ In press in @JACCJournals JACC: Heart Failure today:Endomyocardial Biopsy Characterization of HFpEF and Prevalence of Cardiac Amyloidosis@KSharmaMD @dkassjhu @lryanek @jvaishnavmd @WendyYingMD @vinisubramanya @EE_Brown42@Marc_Halushka @R

Real World Challenges in enrollment of Minorities in Clinical Trials. Over last 2 weeks I consented 5 minorities for different clinical trials for plasma cell disorder @utswcancer. Next 5 tweets

Sharath Rajagopalan

Simply amazing to see the clinical and the QoL improvements noted with #Digoxin in the RATE-AF trial presented at #ESCCongress2020. Among medicine residents, I would attribute less use of digoxin

It’s been over 2 months since the first descriptions of cardiac manifestations of Covid-19. There have been many papers and reviews on this topic. What have we learned about how

Rafael Fonseca MD

WHAT IS THE RISK CLASSIFICATION OF THE t(11;14) in MM?This has been a long-debated question and probably asked in the wrong way. I have always had a special interest in